191 related articles for article (PubMed ID: 23062655)
1. Clinical applications of cost analysis of diabetic macular edema treatments.
Smiddy WE
Ophthalmology; 2012 Dec; 119(12):2558-62. PubMed ID: 23062655
[TBL] [Abstract][Full Text] [Related]
2. Economic considerations of macular edema therapies.
Smiddy WE
Ophthalmology; 2011 Sep; 118(9):1827-33. PubMed ID: 21507488
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema.
Stein JD; Newman-Casey PA; Kim DD; Nwanyanwu KH; Johnson MW; Hutton DW
Ophthalmology; 2013 Sep; 120(9):1835-42. PubMed ID: 23642372
[TBL] [Abstract][Full Text] [Related]
4. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema.
Brown GC; Brown MM; Turpcu A; Rajput Y
Ophthalmology; 2015 Jul; 122(7):1416-25. PubMed ID: 25935787
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
Dewan V; Lambert D; Edler J; Kymes S; Apte RS
Ophthalmology; 2012 Aug; 119(8):1679-84. PubMed ID: 22503301
[TBL] [Abstract][Full Text] [Related]
6. Economic implications of current age-related macular degeneration treatments.
Smiddy WE
Ophthalmology; 2009 Mar; 116(3):481-7. PubMed ID: 19157562
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment with intravitreal triamcinolone before laser for diabetic macular edema: 6-month results of a randomized, placebo-controlled trial.
Gillies MC; McAllister IL; Zhu M; Wong W; Louis D; Arnold JJ; Wong TY
Invest Ophthalmol Vis Sci; 2010 May; 51(5):2322-8. PubMed ID: 20019369
[TBL] [Abstract][Full Text] [Related]
8. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.
Do DV; Schmidt-Erfurth U; Gonzalez VH; Gordon CM; Tolentino M; Berliner AJ; Vitti R; Rückert R; Sandbrink R; Stein D; Yang K; Beckmann K; Heier JS
Ophthalmology; 2011 Sep; 118(9):1819-26. PubMed ID: 21546089
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes.
Lam DS; Chan CK; Mohamed S; Lai TY; Lee VY; Liu DT; Li KK; Li PS; Shanmugam MP
Ophthalmology; 2007 Dec; 114(12):2162-7. PubMed ID: 17459479
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the magnitude and time course of macular thinning induced by different interventions for diabetic macular edema: implications for sequence of application.
Browning DJ; Fraser CM; Powers ME
Ophthalmology; 2006 Oct; 113(10):1713-9. PubMed ID: 16889833
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial.
Gillies MC; McAllister IL; Zhu M; Wong W; Louis D; Arnold JJ; Wong TY
Ophthalmology; 2011 May; 118(5):866-72. PubMed ID: 21232801
[TBL] [Abstract][Full Text] [Related]
12. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
Hutton DW; Stein JD; Glassman AR; Bressler NM; Jampol LM; Sun JK;
JAMA Ophthalmol; 2019 Dec; 137(12):1424-1432. PubMed ID: 31647496
[TBL] [Abstract][Full Text] [Related]
13. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema.
Gillies MC; Simpson JM; Gaston C; Hunt G; Ali H; Zhu M; Sutter F
Ophthalmology; 2009 Nov; 116(11):2182-7. PubMed ID: 19796823
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.
Hutton DW; Stein JD; Bressler NM; Jampol LM; Browning D; Glassman AR;
JAMA Ophthalmol; 2017 Jun; 135(6):576-584. PubMed ID: 28492920
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of treatment of diabetic macular edema.
Pershing S; Enns EA; Matesic B; Owens DK; Goldhaber-Fiebert JD
Ann Intern Med; 2014 Jan; 160(1):18-29. PubMed ID: 24573663
[TBL] [Abstract][Full Text] [Related]
16. The impact of anti-vascular endothelial growth factor agents on visual impairment/blindness prevention in patients with diabetic macular edema and on associated patient and caregiver burden in Japan.
Kitano S; Sakamoto T; Goto R; Fukushima A; Vataire AL; Hikichi Y
J Med Econ; 2019 Mar; 22(3):254-265. PubMed ID: 30550375
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of ranibizumab in the treatment of visual impairment due to diabetic macular edema.
Haig J; Barbeau M; Ferreira A
J Med Econ; 2016 Jul; 19(7):663-71. PubMed ID: 26882365
[TBL] [Abstract][Full Text] [Related]
18. Triple therapy of vitrectomy, intravitreal triamcinolone, and macular laser photocoagulation for intractable diabetic macular edema.
Kang SW; Park SC; Cho HY; Kang JH
Am J Ophthalmol; 2007 Dec; 144(6):878-885. PubMed ID: 17936715
[TBL] [Abstract][Full Text] [Related]
19. Management paradigms for diabetic macular edema.
Mitchell P; Wong TY;
Am J Ophthalmol; 2014 Mar; 157(3):505-13.e1-8. PubMed ID: 24269850
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial.
Mitchell P; Annemans L; Gallagher M; Hasan R; Thomas S; Gairy K; Knudsen M; Onwordi H
Br J Ophthalmol; 2012 May; 96(5):688-93. PubMed ID: 22399690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
